Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:25:46 EDT Sat 10 May 2025
Enter Symbol
or Name
USA
CA



Q:SGMO - SANGAMO THERAPEUTICS INC - https://www.sangamo.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SGMO - Q0.20.665·0.737.60.7002-0.0196-2.72,907.61,8383,2340.7111  0.7327  0.68443.175  0.304119:55:57May 0615 min RT 2¢

Recent Trades - Last 10 of 3234
Time ETExPriceChangeVolume
19:55:57Q0.7103-0.009510
19:55:40Q0.730.0102960
19:54:38Q0.715-0.004810
19:54:32Q0.7161-0.003710
19:53:38Q0.7152-0.004610
19:53:32Q0.7174-0.002410
19:50:19Q0.730.01028
19:47:57Q0.70-0.01985,682
19:47:55Q0.70-0.0198500
19:29:40Q0.730.010224

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-05-06 16:35U:SGMONews ReleaseSangamo Therapeutics Announces First Quarter 2025 Earnings Call
2025-05-06 08:30U:SGMONews ReleaseSangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease
2025-04-28 16:31U:SGMONews ReleaseSangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
2025-04-03 16:01U:SGMONews ReleaseSangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
2025-03-17 16:01U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
2025-03-06 16:05U:SGMONews ReleaseSangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
2025-02-06 08:05U:SGMONews ReleaseSangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
2024-12-30 16:15U:SGMONews ReleaseSangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer's Decision to Cease Development of Giroctocogene Fitelparvovec
2024-12-19 02:30U:SGMONews ReleaseSangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
2024-12-19 02:30U:SGMONews ReleaseAstellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
2024-11-19 16:15U:SGMONews ReleaseSangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
2024-11-12 16:01U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
2024-11-04 16:15U:SGMONews ReleaseSangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
2024-10-22 08:05U:SGMONews ReleaseSangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025
2024-08-06 16:01U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results
2024-08-06 08:05U:SGMONews ReleaseSangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases
2024-07-30 16:15U:SGMONews ReleaseSangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
2024-07-24 06:55U:SGMONews ReleaseSangamo Therapeutics Reports on Pfizer's Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate